Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (73.08 KB, 1 trang )
300 mg/kg/day IV or PO), which enhances secretion of organic acids, should be considered for patients
with isovaleric acidemia. Patients with holocarboxylase synthetase, biotinidase deficiency, or propionic
acidemia may improve with biotin (10 to 40 mg/day given PO or NG), those with maple syrup urine
disease may benefit from thiamine, and those with methylmalonic academia may benefit from
hydroxocobalamin (vitamin B12 ; 1 mg IM). It is usually not imperative that these cofactor therapies be
administered in the ED. Antibiotics should be administered as clinically indicated for infection.
Administration of an oral, broad-spectrum antibiotic to reduce gut flora, a significant source of organic
acids, may be beneficial but usually is not initiated in the ED. Efficacy of emergent treatment is
monitored by ongoing assessment of mental status, fluid and cardiovascular status, signs of bleeding, and
measurement of electrolytes, glucose, ammonia, and blood gas levels every 4 to 6 hours until the patient
is stabilized. Resolution of metabolic crisis usually takes days to weeks. The New England Consortium of
Metabolic Programs details treatment for specific organic acidemias on their website
.
UREA CYCLE DEFECTS
Goals of Treatment
For urea cycle defects, the specific goals of acute treatment are to eliminate protein intake, avoid protein
catabolism, remove ammonia, and treat any precipitating illness.
Current Understanding
Disorders of the urea cycle result in toxic accumulation of ammonia generated by the catabolism of
protein. Urea cycle disorders include carbamoyl phosphate synthetase 1 deficiency, ornithine
transcarbamylase deficiency, citrullinemia, argininosuccinate lyase deficiency, and arginase deficiency.
Ammonia, in excess, is a neurotoxin that results in cerebral edema as well as brainstem dysfunction.
Clinical Considerations
Assessment
Patients with severe enzyme deficiency present within the first few days of life, following consumption
of protein in breast milk or formula. Those with partial deficiency usually present within the first few
months of life, but may present even as adults, after intake of a quantity of protein that exceeds their
metabolic capacity. The most severe forms include carbamoyl phosphate synthetase 1 deficiency and